<DOC>
	<DOCNO>NCT00000669</DOCNO>
	<brief_summary>To determine safety maximum tolerate dose ( MTD ) 2',3'-dideoxyinosine ( ddI ) , give orally intravenously , infant child AIDS . The study also measure bloodstream cerebrospinal fluid ( CSF ) level administer drug , provide preliminary assessment effectiveness ddI HIV replication . AMENDED : Based safety establish first dose phase 52 week long term dose data adult , dose period extend 104 week . Original design : Information presently available indicates ddI high antiviral activity less apparent toxicity zidovudine ( AZT ) ( drug presently use treat AIDS ) .</brief_summary>
	<brief_title>A Phase I Safety Pharmacokinetics Study 2',3'-Dideoxyinosine ( ddI ) Administered Twice Daily Infants Children With AIDS Symptomatic HIV Infection</brief_title>
	<detailed_description>AMENDED : Based safety establish first dose phase 52 week long term dose data adult , dose period extend 104 week . Original design : Information presently available indicates ddI high antiviral activity less apparent toxicity zidovudine ( AZT ) ( drug presently use treat AIDS ) . AMENDED : Dosing proceed 104 week dose level . Original design : Five patient treat initial dose level . Because ddI stable acid environment stomach , oral dos ddI follow administration antacid . An alternative method dose mix reconstitute ddI appropriate volume Maalox TC Mylanta II . In order determine MTD , successive group 5 patient enter study high dose level 3 patient experience 3 week dose significant toxicity develop . Patients assign treatment group order enrol . Dosing proceeds 16 week dose level . However , consideration give escalate patient enter low dose next dose level 10 week dose . The dose escalation continue toxicity require dose modification find 2 5 group .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Aerosolized pentamidine Pneumocystis carinii pneumonia ( PCP ) prophylaxis drug extend child . Acute therapy exceed 7 day oral intravenous acyclovir herpes simplex infection . Trimethoprim / sulfamethoxazole Pneumocystis carinii infection course study discretion investigator discussion sponsor . Symptomatic therapy analgesic , antihistamine , antiemetic , antidiarrheal agent , supportive therapy deem necessary principal investigator . Patients must : Diagnosis AIDS define CDC meeting CDC P2 classification . Patients must free opportunistic infection serious bacterial , fungal , parasitic infection time entry study . Life expectancy &gt; 6 month . Parent guardian ( patient applicable ) able give inform consent . Available followup least 6 month . Allowed : Hemophilia . Exclusion Criteria Coexisting Condition : Children follow exclude : Chronic hematologic disorder unrelated coagulation defect , hemoglobinopathy , ITP . Intractable diarrhea . No venous access . History seizure within previous 2 year currently require anticonvulsant control . Currently active heart disease evidence cardiac arrhythmia significant abnormality routine electrocardiography ( ECG ) shorten fraction &lt; 10 percent echocardiogram . Renal disease . Any clinical condition opinion investigator make patient unsuitable study . Concurrent Medication : Excluded : Antiretroviral drug . Zidovudine ( AZT ) . AL 721 . Interferon . Corticosteroids . Immunomodulating drug . Other systemic investigation agent . Ribavirin . Rifampin , barbiturates , potent inducer inhibitor drugmetabolizing enzyme . Cytotoxic anticancer therapy . H2 blocker . Intravenous ketoconazole . Immunoglobulin preparation . Children follow exclude : Chronic hematologic disorder unrelated coagulation defect , hemoglobinopathy , ITP . Intractable diarrhea . No venous access . History seizure within previous 2 year currently require anticonvulsant control . Currently active heart disease evidence cardiac arrhythmia significant abnormality routine electrocardiography ( ECG ) shorten fraction &lt; 10 percent echocardiogram . Renal disease . Any clinical condition opinion investigator make patient unsuitable study . Renal disease . Prior Medication : Excluded : Any prior therapy opinion investigator would make patient unsuitable study . Excluded within 2 week study entry : Trimethoprim / sulfamethoxazole . Excluded within 1 month study entry : Study drug antiretroviral drug systemic investigational agent . Any agent know potent inducer inhibitor drug metabolize enzyme . H2 blocker . Ketoconazole . Immunoglobulin preparation . Excluded within 3 month study entry : Ribavirin . Excluded : Zidovudine ( AZT ) &gt; 6 month . Cytotoxic anticancer therapy . Prior Treatment : Excluded within 4 week study entry : Blood transfusion . Lymphocyte transfusion immune reconstitution . Bone marrow transplant .</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>October 1996</verification_date>
	<keyword>Didanosine</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
</DOC>